Neuroprotective capabilities of TSA against cerebral ischemia/reperfusion injury via PI3K/Akt signaling pathway in rats

International Journal of Neuroscience

Volumn 125, Issue 2, 2015, Pages 140-146

  Ma, Xiao Hui ^a   Gao, Qiang ^b   Jia, Zhen ^b   Zhang, Ze Wei ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Akt; Cerebral ischemia reperfusion injury; P Akt; PI3K Akt signal pathway; TSA

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRICHOSTATIN A; WORTMANNIN; ANDROSTANE DERIVATIVE; ENZYME INHIBITOR; HYDROXAMIC ACID; NEUROPROTECTIVE AGENT; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; RAT; REPERFUSION INJURY; ANALYSIS OF VARIANCE; ANIMAL; BRAIN INJURIES; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; NERVOUS SYSTEM DISEASES; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANDROSTADIENES; ANIMALS; BRAIN INJURIES; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HYDROXAMIC ACIDS; MALE; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 84919625549     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2014.912217     Document Type: Article

References (38)

1. Frantseva MV, Carlen PL, Perez Velazquez JL. Dynamics of intracellular calcium and free radical production during ischemia in pyramidal neurons. Free Radic Biol Med 2001;31(10):1216-27.
2. Kamada H, Nito C, Endo H, Chan PH. Bad as a converging signaling molecule between survival PI3-K/Akt and death JNK in neurons after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2007;27(3):521-33.
3. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20(1):84-91.
4. HE M, GUO Q. Cerebral protection of trichostatin: a preconditioning in rats with middle cerebral artery occlusion and the relationship between trichostatin A and IL-1β. J Cent South Univ (Med Sci). 2012;37(4):379-83.
5. Kim HJ, Rowe M, Ren M, et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007;321(3): 892-901.
6. Belayev L, Alonso OF, Busto R, et al. Middle cerebral artery occlusion in the rat by intraluminal suture neurological and pathological evaluation of an improved model. Stroke 1996;27(9):1616-23.
7. Leoni F, Zaliani A, Bertolini G, et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci 2002;99(5):2995-3000.
8. Chakravortty D, Koide N, Kato Y, et al. The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells. J Endotoxin Res 2000;6(3):243-7.
9. Kim HJ, Rowe M, Ren M, et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007;321(3):892-901.
10. Blanchard F, Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 2005;10(3):197-204.
11. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-κB activation and cellular proteasome activity. J Biol Chem 2001;276(48):44641-6.
12. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-κB activation. J Biol Chem 2006;281(9): 5612-22.
13. Yu Z, Zhang W, Kone BC. Histone deacetylases augment cytokine induction of the iNOS gene. J Am Soc Nephrol 2002;13(8):2009-17.
14. Klampfer L, Huang J, Swaby LA, Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 2004;279(29):30358-68.
15. Adcock I. HDAC inhibitors as anti-inflammatory agents. Br J Pharmacol 2007;150(7):829.
16. Ryu H, Lee J, Olofsson BA, et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci 2003;100(7):4281-6.
17. Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999;72(2):879-82.
18. Bown CD, Wang JF, Young LT. Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology 2000;39(11):2162-9.
19. Chuang DM, Hough C, Senatorov VV. Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative disease. Annu Rev Pharmacol Toxicol 2005;45: 269-90.
20. Kanai H, Sawa A, Chen R, et al. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J 2004;4(5):336-44.
21. Fukumoto T, Morinobu S, Okamoto Y, et al. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001;158(1):100-106.
22. Chen PS, Peng GS, Li G, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006;11(12):1116-25.
23. Yoshida M, Matsuyama A, Komatsu Y, Nishino N. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 2003;10(22):2351-8.
24. FinninMS, Donigian JR, Cohen A, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHAinhibitors. Nature 1999;401(6749):188-93.
25. Stein A, Tang X, Guo Y, et al.Delayed adaptation of the heart to stress: late preconditioning. Stroke; A Journal of Cerebral Circulation 2004;35(11 Suppl 1):2676-9.
26. Yildirim F, Gertz K, Kronenberg G, et al. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol 2008;210(2): 531-42.
27. Yu L, Lu M, Wang P, Chen X. Trichostatin A ameliorates myocardial ischemia/reperfusion injury through inhibition of endoplasmic reticulum stress-induced apoptosis. Arch Med Res 2012;43(3):190-96.
28. Fleiss B, Nilsson M, Blomgren K, Mallard C. Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury. J Neuroinflammation 2012;9:70.
29. Camelo S, Iglesias AH, Hwang D, et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin: a ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2005;164(1):10-21.
30. Zhou C, Qiu L, Sun Y, et al. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSAs effect on cell death and migration in human ovarian cancer cells. Int J Oncol 2006;29(1):269-78.
31. Yu Z, Kone BC. Targeted histone H4 acetylation via phosphoinositide 3-kinase-and p70s6-kinase-dependent pathways inhibits iNOS induction in mesangial cells. Am J Physiol Renal Physiol 2006;290(2):F496-F502.
32. Zhao H, Shimohata T, Wang JQ, et al. Akt contributes to neuroprotection by hypothermia against cerebral ischemia in rats. J Neurosci 2005;25(42):9794-806.
33. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2013;38(2):209-23.
34. Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol Cell Biol 2008;9(5):378-90.
35. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91(2):231-41.
36. del Peso L, González-García M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278(5338):687-9.
37. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-κB by the Akt/PKB kinase. Current Biology 1999;9(11):601-4.
38. Ozes ON, Mayo LD, Gustin JA, et al. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401(6748):82-5.